机构:[1]Peking University Institute of Hematology, Peking University People’s Hospital, Beijing, China[2]National Clinical Research Center for Hematologic Disease, Beijing, China[3]First Afliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China江苏省人民医院[4]Pukou CLL Center, Pukou Division of Jiangsu Province Hospital, Nanjing, China江苏省人民医院[5]Nanfang Hospital of Southern Medical University, Guangzhou, China[6]Nanfang Hospital, GUANGZHOU, China[7]Department of Hematology, West China Hospital, Sichuan University, Chengdu, China四川大学华西医院[8]Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China[9]China-Japan Friendship Hospital, Beijing, China[10]FuXing hospital,Capital Medical University, Beijing, China[11]Peking University First Hospital, Beijing, China[12]Beijing Tongren Hospital, Beijing, China首都医科大学附属北京同仁医院首都医科大学附属同仁医院[13]Xuanwu Hospital, Capital Medical University, Beijing, China首都医科大学宣武医院[14]Shanxi Province Cancer Hospital, Taiyuan, China[15]Department of Hematology, Shanxi Province Cancer Hospital/ Shanxi Hospital Afliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Afliated to Shanxi Medical University, Taiyuan, China[16]Chinese PLA General Hospital, Beijing, China[17]Peking University People’s Hospital, Beijing, China[18]Pukou CLL Center, Pukou Division of Jiangsu Province Hospital, Nanjing, China江苏省人民医院
第一作者机构:[1]Peking University Institute of Hematology, Peking University People’s Hospital, Beijing, China[2]National Clinical Research Center for Hematologic Disease, Beijing, China
推荐引用方式(GB/T 7714):
Yang Shenmiao,Zhu Huayuan,Feng Ru,et al.Efficacy and Safety of Zanubrutinib Monotherapy in Real-World Chinese CLL/SLL Patients[J].BLOOD.2024,144:6773-6774.doi:10.1182/blood-2024-206560.
APA:
Yang, Shenmiao,Zhu, Huayuan,Feng, Ru,Guo, Xutao,Niu, Ting...&Li, Jianyong.(2024).Efficacy and Safety of Zanubrutinib Monotherapy in Real-World Chinese CLL/SLL Patients.BLOOD,144,
MLA:
Yang, Shenmiao,et al."Efficacy and Safety of Zanubrutinib Monotherapy in Real-World Chinese CLL/SLL Patients".BLOOD 144.(2024):6773-6774